| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/05/2006 | US20060003955 Immunostimulatory nucleic acid molecules |
| 01/05/2006 | US20060003928 Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| 01/05/2006 | US20060003451 Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| 01/05/2006 | US20060003445 Method and device for detecting feline immunodeficiency virus |
| 01/05/2006 | US20060003379 Smad6 and uses thereof |
| 01/05/2006 | US20060003364 GLUT1 transporters expressed in cancer cells |
| 01/05/2006 | US20060003362 ENT1 transporters expressed in cancer cells |
| 01/05/2006 | US20060003361 SMVT transporters expressed in cancer cells |
| 01/05/2006 | US20060003346 Method for treating hepatitis |
| 01/05/2006 | US20060003316 Immunogenic compositions derived from poxviruses and methods of using same |
| 01/05/2006 | US20060002993 Genetic engineered protein; transgenic animal, used to elicit a humoral or cellular immune response |
| 01/05/2006 | US20060002990 Local nasal immunotherapy with allergen strip for allergic rhinitis |
| 01/05/2006 | US20060002969 Methods for reducing the foreign body reaction |
| 01/05/2006 | US20060002962 Method of treating allergy and infection by eliciting an IGA antibody response |
| 01/05/2006 | US20060002961 Immunogens; Streptococcus pneumoniae polysaccharide-protein conjugate/antigen, and adjuvant which induces (cytotoxic T) lymphocytes |
| 01/05/2006 | US20060002960 GM1 binding deficient exotoxins for use as immunoadjuvants |
| 01/05/2006 | US20060002959 Skin-sctive adjuvants for transcutaneous immuization |
| 01/05/2006 | US20060002958 Attenuation of metapneumovirus |
| 01/05/2006 | US20060002957 Method and device for detecting feline immunodeficiency virus |
| 01/05/2006 | US20060002956 Minicells as vaccines |
| 01/05/2006 | US20060002953 Molecular differences between species of the M. tuberculosis complex |
| 01/05/2006 | US20060002952 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 01/05/2006 | US20060002951 Inhibition of the tRNALys3-primed initiation of reverse transcription in HIV-1 by APOBEC3G |
| 01/05/2006 | US20060002950 Immunomodulatory protein derived from Trypanosomes and uses thereof |
| 01/05/2006 | US20060002949 Transcutaneous immunization by applying a formulation with an antigen or a polynucleotide coding for an antigen epicutaneously to the skin to penetrate through the stratum comeum without physical or chemical penetration of the dermis; side effect reduction; vaccines; drug delivery |
| 01/05/2006 | US20060002948 Polypeptide isolated from Dermatophagoides; use of polypeptides, polynucleotides and/or antibodies in therapy and diagnosis of allergic disorders; genetic engineering |
| 01/05/2006 | US20060002947 Ii-key/antigenic epitope hybrid peptide vaccines |
| 01/05/2006 | US20060002946 Targeted immunogens |
| 01/05/2006 | US20060002945 Non-sensitive antigenic peptide derived from fc portion of the epsilon heavy chain of immunoglobulin-E for use in treatment and prevention of allergic disorders |
| 01/05/2006 | US20060002944 by administering a CRIg ( a macrophage specific receptor) polypeptide or its agonist; autoimmune, respiratory, kidney, skin, cardiovascular disorders |
| 01/05/2006 | US20060002943 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 01/05/2006 | US20060002942 Calicheamicin conjugates |
| 01/05/2006 | US20060002941 Compositions comprising immune response altering agents and methods of use |
| 01/05/2006 | US20060002940 Method of immunotherapy |
| 01/05/2006 | US20060002939 Monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal; light and heavy chains comprising complementarity determining regions |
| 01/05/2006 | US20060002938 Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation |
| 01/05/2006 | US20060002937 Methods for treating conditions associated with MASP-2 dependent complement activation |
| 01/05/2006 | US20060002936 Method of modulating platelet activation |
| 01/05/2006 | US20060002935 Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| 01/05/2006 | US20060002934 Egf receptor antagonists in the treatment of gastric cancer |
| 01/05/2006 | US20060002933 Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| 01/05/2006 | US20060002932 Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| 01/05/2006 | US20060002931 Antibodies of angiogenesis inhibiting domains CD148 |
| 01/05/2006 | US20060002930 Treatment of disorders |
| 01/05/2006 | US20060002929 Monoclonal antibodies |
| 01/05/2006 | US20060002928 Administering an IgM immunoglobulin antibody that binds to B7-DC polypeptides on a cell; antiasthma, antitussive, bronchodilator, antihistamine, and antiallergen agents; vaccines |
| 01/05/2006 | US20060002927 Use of anti-cd1 antibodies for the modulation of immune responses |
| 01/05/2006 | US20060002926 isolated and/or recombinant; characterized by high affinity binding of one or more chemokines, such as eotaxin, RANTES and/or MCP-3, and/or the ability to stimulate a (one or more) cellular response(s) (e.g., chemotaxis, exocytosis, release of one or more inflammatory mediators) |
| 01/05/2006 | US20060002924 Conjugate of notch signalling pathway modulators and their use in medical treatment |
| 01/05/2006 | US20060002923 Recombinant anti-osteopontin antibody and use thereof |
| 01/05/2006 | US20060002922 Method for preventing or treating obesity by modulating the activities of the pentose phosphate patway |
| 01/05/2006 | US20060002921 Using immunoglobulin specific to lymphocyte receptor as tool in treatment and prevention of transplant rejection; immunosuppressant |
| 01/05/2006 | US20060002920 different epitopes are located within the binding domain of the natural ligand(s) of said receptor; first and second antigen-binding site binds to a different epitope on the same EGFR molecule; anticarcinogenicb antimetastasis agents |
| 01/05/2006 | US20060002919 15625 receptor, a novel G-protein coupled receptor |
| 01/05/2006 | US20060002906 Tolerizing allografts of pluripotent stem cells |
| 01/05/2006 | US20060002905 Mutant forms of EtxB and CtxB and their use as carriers |
| 01/05/2006 | US20060002897 Plasmid for tissue targeted treatment of tumors; antitumor agents |
| 01/05/2006 | US20060002896 Method of generating recombinant MVA |
| 01/05/2006 | US20060002892 Lectin-like transcript (LLTI); Natural killer cells; antitumor agents; quantitative analysis; human lectin transcription factor |
| 01/05/2006 | US20060002891 Cytomodulating conjugates of members of specific binding pairs |
| 01/05/2006 | US20060002862 High pressure spray-dry of bioactive materials |
| 01/05/2006 | US20060002854 Conjugate of therapeutic moiety linked to peptide having the amino acid sequence CGKRK, length < 400 residues, or a conservative variant or peptidomimetic; anticarcinogenic, -tumor agents; tissue-targeted therapy; side effect reduction; binds cognate receptor; angiogenesis inhibitors |
| 01/05/2006 | DE102004062258B3 New hydroxypyrimidone, hydroxypyridinone or dihydroxybenzene derivatives useful for preparing conjugates of biomolecules useful as magnetic resonance contrast agents |
| 01/05/2006 | DE102004028156A1 Combination of radio waves and one or more of monoclonal antibodies, tyrosine-kinase inhibitors, angiogenesisi inhibitors, farnesyl transferase inhibitors, topoisomerase - I or II inhibitors, cytokine and antisense oligonucleotides |
| 01/05/2006 | CA2578592A1 Conjugates and therapeutic uses thereof |
| 01/05/2006 | CA2572193A1 Treatment of conditions involving oligodendrocytes with sp35 based agents |
| 01/05/2006 | CA2572015A1 Fc-interferon-beta fusion proteins |
| 01/05/2006 | CA2571852A1 Inhibition of infiltration, and cell killing agent |
| 01/05/2006 | CA2571673A1 Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor |
| 01/05/2006 | CA2571565A1 Dimensional analysis of saccharide conjugates with gpc & sec-mals |
| 01/05/2006 | CA2571316A1 Vaccination of skunks and/or mongooses against rabies |
| 01/05/2006 | CA2570849A1 Optimized dosing with anti-cd4 antibodies for tolerance induction in primates |
| 01/05/2006 | CA2570778A1 Prrsv subunit vaccines |
| 01/05/2006 | CA2568982A1 Polysaccharide derivatives and uses in induction of an immune response |
| 01/05/2006 | CA2568661A1 Human monoclonal antibodies to fc gamma receptor i (cd64) |
| 01/04/2006 | EP1612555A1 Cryptic peptides for use in inducing immunologic tolerance |
| 01/04/2006 | EP1612281A2 Methods for assessing patients with acute myeloid leukemia |
| 01/04/2006 | EP1612272A2 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 01/04/2006 | EP1612269A1 Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen |
| 01/04/2006 | EP1612268A1 Receptor ligand VEGF-C |
| 01/04/2006 | EP1612224A1 Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine |
| 01/04/2006 | EP1612219A1 Allergen from house-dust mites |
| 01/04/2006 | EP1612217A2 Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| 01/04/2006 | EP1611897A2 Whole or disrupted insect cells as adjuvant for antigens |
| 01/04/2006 | EP1611154A1 Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of ifn-gamma activity |
| 01/04/2006 | EP1610820A1 High concentration antibody and protein formulations |
| 01/04/2006 | EP1610819A2 Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form |
| 01/04/2006 | EP1610818A1 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 01/04/2006 | EP1610817A2 Infectious bronchitis virus with an altered spike gene |
| 01/04/2006 | EP1610815A2 Francisella strain for live vaccine |
| 01/04/2006 | EP1610814A1 Therapeutic composition for autoimmune conditions |
| 01/04/2006 | EP1610757A2 Profiling conformational variants, antibody compositions and methods of using the same |
| 01/04/2006 | EP1357941B1 Therapeutical use of anti-mag antibody for the treatment of ischemic stroke |
| 01/04/2006 | EP1311677B1 Regulation of human p2y1-like g protein-coupled receptor |
| 01/04/2006 | EP1294390B1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| 01/04/2006 | EP1146881B1 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 01/04/2006 | EP1053325B1 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
| 01/04/2006 | EP0970243B1 Diagnosis and treatment of glaucoma |
| 01/04/2006 | EP0966545B1 Method for typing of minor histocompatibility antigen ha-1 |
| 01/04/2006 | EP0927255B1 Vaccine production of the bacillus anthracis protective antigen |